Palmidrol

Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application by the United States Patent and Trademark Office (USPTO) for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders. The patent application stems from Clearmind’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC). This therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s neuroplastic properties to reduce impulsivity and reward-seeking behavior, which, together with PEA, has shown a synergistic pharmacological effect and therefore potentially offering a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today. This publication builds on Clearmind’s intellectual property portfolio. The Company has filed 13 patents related to its collaboration with SciSparc, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways. “The publication of this U.S. patent application represents yet another advancement in our mission to pioneer safe and effective, next-generation treatments for binge behaviors,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “By combining MEAI’s unique neuroplastic profile with PEA’s synergistic benefits, we’re aiming to address a significant unmet needs in addiction medicine. We believe that this strengthens our position as a leader in psychedelic therapeutics and paves the way for additional clinical development.” About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com or contact: Investor Relationsinvest@clearmindmedicine.com Telephone: (604) 260-1566US: CMND@crescendo-ir.com General InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how the combination of MEAI and PEA potentially offers a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today, the Company’s mission to pioneer safe and effective, next-generation treatments for binge behaviors, its aim to address significant unmet needs in addiction medicine and additional clinical development. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

转自：蒲公英Ouryao 综合：无忧 9月4日，美迪西发布公告称被客户鸿绪生物起诉，涉诉金额超1.59亿元。 值得注意的是这份委托合同金额557.6万元，该项目已经在国内获得临床批件，尚有10%，即55.76万元尾款尚未支付。 这一巨额索赔案件让CRO行业的合同风险问题再次成为焦点。 天价索赔背后的合同纠纷 根据公告披露，此次纠纷源于2020年12月18日美迪西普亚与鸿绪生物签署的一份《技术服务合同》。鸿绪生物委托美迪西普亚对其I类生物技术药（多肽）进行非临床安全性评价研究，以支持中美双报。 合同明确规定，美迪西普亚需在8个月内完成分析检测、安全性评价、翻译和SEND（非临床数据交换标准）转化四个试验项目，并提供中文和英文两个版本的试验报告。 值得注意的是，该项目于2023年12月14日获得中国国家药监局的临床试验批件（受理号CXHL2301060），表面看来项目进展顺利。 然而，鸿绪生物却认为美迪西普亚在履行合同过程中存在违约行为，要求解除合同并赔偿损失。不过，据公告描述，原告鸿绪生物称美迪西普亚“在履行合同过程中存在违约行为”，不过并未提及具体有哪些违约行为。 1.59亿天价索赔的构成 鸿绪生物提出的诉讼请求包括： 确认合同于诉状送达被告之日起解除 要求美迪西普亚支付以已付款501.84万元为基础，合同解除以前延期履行合同的违约金（暂计违约金为351.54万元） 返还已支付的服务费501.84万元 赔偿各项损失合计1.5亿元 要求被告承担本案的诉讼费用、保全费用 案件诉讼金额共计约1.59亿元，不包含诉讼费用、保全费用。 悬殊对比引发疑问 这场纠纷的原始合同金额仅为558万元，而鸿绪生物提出的索赔金额却高达1.59亿元，相差近28倍之多。据披露，鸿绪生物尚欠付美迪西普亚合同款56万元。 这种悬殊的对比让人不禁疑问：为何一项原本金额不大的合作会引发如此巨大的索赔？1.59亿元的损失赔偿依据何在？这些问题都成为了市场关注的焦点。 类似案例屡见不鲜 美迪西并非首家卷入合同纠纷的CRO企业。近年来，随着行业竞争加剧，类似案例时有发生： 案例一：FSD Pharma与Syneos Health临床CRO纠纷 2023年7月，纳斯达克上市的Biotech公司FSD Pharma与全球CRO巨头Syneos对簿公堂。Syneos声称因FSD-201的临床II期试验失败，FSD Pharma欠付其390万美元的损害赔偿金和利息，同时还要求FSD Pharma支付相关法律费用。 案例二：水仙药业与鑫开元医药研发纠纷 2024年年初，上市公司青山纸业发布控股子公司重大诉讼公告。 因技术开发合同纠纷，青山纸业控股子公司漳州水仙药业股份有限公司及孙公司漳州无极药业有限公司，起诉CRO北京鑫开元医药科技有限公司及其母公司海南华氏医药控股集团有限公司，涉案总金额为4674.87万元。 青山纸业公告称，北京鑫开元资金周转困难，经营有恶化迹象，受其影响，旗下控股子公司水仙药业委托鑫开元公司研发的克立硼罗软膏和五个口服固体制剂等六个项目，工作进展缓慢，目前处于停滞状态，研发进度落后于合同约定。 给行业的启示 美迪西此次卷入的巨额合同纠纷，既是单个企业的偶发事件，也是行业发展阶段的必然现象。随着CRO行业从高速增长期步入成熟期，企业之间的竞争将从单纯的规模和价格竞争，转向质量、服务和风险管理能力的综合比拼。 如何平衡业务扩张与风险控制，将成为所有CRO企业必须面对的课题。对于美迪西而言，此次诉讼既是一次挑战，也是提升内部管理水平的契机。事件后续发展如何，我们将继续保持关注。 值得一提的是，此类纠纷往往涉及复杂的专业技术问题，通常需要漫长的审理过程和专业鉴定，最终结果如何还存在很大不确定性。